Carregant...

FAILURE OF HYPOMETHYLATING AGENT-BASED THERAPY IN MYELODYSPLASTIC SYNDROMES

Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have been shown to improve transfusion requirements and change the natural history of the disease. However, with increasing cumulative cli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kadia, Tapan M., Jabbour, Elias, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098768/
https://ncbi.nlm.nih.gov/pubmed/21943675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2011.04.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!